Increase in resistance rates of H.pylori isolates to metronidazole and tetracycline-comparison of three 3-year studies

Archives of Iranian Medicine

Volumn 13, Issue 3, 2010, Pages 177-187

  Siavoshi, Farideh ^a   Saniee, Parastoo ^a   Latifi Navid, Saeid ^b   Massarrat, Sadegh ^c   Sheykholeslami, Arghavan ^c  

^a UNIVERSITY OF TEHRAN   (Iran)

^b UNIVERSITY OF MOHAGHEGH ARDABILI   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

H.pylori; Metronidazole; Resistance; Tetracycline

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; FURAZOLIDONE; METRONIDAZOLE; TETRACYCLINE;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIUM ISOLATE; COMPARATIVE STUDY; CONTROLLED STUDY; DISK DIFFUSION; DRUG USE; DYSPEPSIA; FEMALE; HELICOBACTER PYLORI; HUMAN; IRAN; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PLASMID; PUBLIC HEALTH PROBLEM;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; AMOXICILLIN; CHI-SQUARE DISTRIBUTION; CLARITHROMYCIN; COHORT STUDIES; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; FURAZOLIDONE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; IRAN; MALE; METRONIDAZOLE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PROBABILITY; RETROSPECTIVE STUDIES; SEX FACTORS; TETRACYCLINE; YOUNG ADULT;

EID: 77953071160     PISSN: 10292977     EISSN: 17353947     Source Type: Journal    
DOI: None     Document Type: Article

References (82)

1. Ernst PB, Crowe SE, Reyes VE. How does Helicobacter pylori cause mucosal damage? The inflammatory response. Gastroenterology. 1997; 113(suppl 6): S35 - S42; discussion S50.
2. Peura DA. Helicobacter pylori and ulcerogenesis. Am J Med. 1996; 100: 19S - 25S; discussion S-6S.
3. Parsonnet J, Hansen S, Rodriguez L, Gelb AB, Warn-ke RA, Jellum E, et al. Helicobacter pylori infection and gastric lymphoma. N Engl J Med. 1994; 330: 1267-1271.
4. Parsonnet J, Friedman GD, Vandersteen DP, Chang Y, Vogelman JH, Orentreich N, et al. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med. 1991; 325: 1127-1131.
5. Alexander GA, Brawley OW. Association of Helico-bacter pylori infection with gastric cancer. Mil Med. 2000; 165: 21-27.
6. Neubauer A, Thiede C, Morgner A, Alpen B, Ritter M, Neubauer B, et al. Cure of Helicobacter pylori infection and duration of remission of low-grade gastric mucosa-associated lymphoid tissue lymphoma. J Natl Cancer Inst. 1997; 89: 1350-1355.
7. Valle J, Kekki M, Sipponen P, Ihamaki T, Siurala M. Long-term course and consequences of Helicobacter pylori gastritis. Results of a 32-year follow-up study. Scand J Gastroenterol. 1996; 31: 546-550.
8. Malfertheiner P, Megraud F, O'Morain C, Hungin AP, Jones R, Axon A, et al. Current concepts in the management of Helicobacter pylori infection--the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther. 2002; 16: 167-180.
9. Soll AH. Consensus conference. Medical treatment of peptic ulcer disease. Practice guidelines. Practice Parameters Committee of the American College of Gastroenterology. JAMA. 1996; 275: 622-629.
10. Parsonnet J, Harris RA, Hack HM, Owens DK. Modelling cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer: a mandate for clinical trials. Lancet. 1996; 348: 150-154.
11. El-Omar EM, Oien K, Murray LS, El-Nujumi A, Wirz A, Gillen D, et al. Increased prevalence of precancerous changes in relatives of gastric cancer patients: critical role of H.pylori. Gastroenterology. 2000; 118: 22-30.
12. Uemura N, Okamoto S. Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer in Japan. Gastroenterol Clin North Am. 2000 Dec; 29: 819-827.
13. Megraud F. Resistance of Helicobacter pylori to antibiotics. Aliment Pharmacol Ther. 1997; 11 (suppl 1): 43-53.
14. Aguilar GR, Ayala G, Fierros-Zarate G. Helicobacter pylori: recent advances in the study of its pathoge-nicity and prevention. Salud Publica Mex. 2001; 43: 237-247.
15. Banatvala N, Mayo K, Megraud F, Jennings R, Deeks JJ, Feldman RA. The cohort effect and Helicobacter pylori. JInfect Dis. 1993; 168: 219-221.
16. Parsonnet J. Helicobacter pylori: the size of the problem. Gut. 1998; 43 (suppl 1): S6-S9.
17. Zaat JO, Mank TG, Assendelft WJ. A systematic review on the treatment of giardiasis. Trop Med Int Health. 1997; 2: 63-82.
18. Schwebke JR. Metronidazole: utilization in the obstetric and gynecologic patient. Sex Transm Dis. 1995; 22: 370-376.
19. Mitchell DA. Metronidazole: its use in clinical dentistry. J Clin Periodontol. 1984; 11: 145-158.
20. Chopra I, Roberts M. Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol Mol Biol Rev. 2001; 65: 232-260.
21. Yanagihara K, Tomono K, Imamura Y, Kaneko Y, Kuroki M, Sawai T, et al. Effect of clarithromycin on chronic respiratory infection caused by Pseudomonas aeruginosa with biofilm formation in an experimental murine model. J Antimicrob Chemother. 2002; 49: 867-870.
22. Feder HM Jr., Gerber MA, Randolph MF, Stelmach PS, Kaplan EL. Once-daily therapy for streptococcal pharyngitis with amoxicillin. Pediatrics. 1999; 103: 47-51.
23. Turck M, Handsield HH, Holmes KK. Amoxicillin in the treatment of urinary tract infections. J Infect Dis. 1974; 129 (suppl): S248-S249.
24. Webster BH. Furazolidone in the treatment of giar diasis. Am J Dig Dis. 1960; 5: 618-622.
25. Dzidic S, Suskovic J, Kos B. Antibiotic resistance mechanisms in bacteria: biochemical and genetic 39. spects. Food technolBiotechnol. 2008; 46: 11-21.
26. Aminov RI, Mackie RI. Evolution and ecology of antibiotic resistance genes. FEMS Microbiol Lett. 2007; 271: 147-161.
27. Sjolund M, Tano E, Blaser MJ, Andersson DI, Eng- 40. strand L. Persistence of resistant Staphylococcus epi-dermidis after single course of clarithromycin. Emerg InfectDis. 2005; 11: 1389-1393.
28. Sjolund M, Wreiber K, Andersson DI, Blaser MJ, 41. Engstrand L. Long-term persistence of resistant En-terococcus species after antibiotics to eradicate He-licobacter pylori. Ann Intern Med. 2003; 139: 483-487.
29. Sullivan A, Edlund C, Nord CE. Effect of antimicrobial agents on the ecological balance of human mi-croflora. Lancet Infect Dis. 2001; 1: 101-114.
30. Courvalin P. Transfer of antibiotic resistance genes 43. between gram-positive and gram-negative bacteria. Antimicrob Agents Chemother. 1994; 38: 1447-1451.
31. Vladimir B. Mechanisms of Action of Antibiotics 44. and Mycotoxins. In: Vladimir B, ed. Bioactive Secondary Metabolites of Microorganisms. Amsterdam, The Netherlands: Elsevier Science; 1994: 297-375.
32. Dzidic S, Bedekovic V. Horizontal gene transfer- 45. emerging multidrug resistance in hospital bacteria. Acta Pharmacol Sin. 2003; 24: 519-526.
33. Summers AO. Genetic linkage and horizontal gene transfer, the roots of the antibiotic multi-resistance problem. Anim Biotechnol. 2006; 17: 125-135. 46.
34. Paoluzi P, Iacopini F, Crispino P, Nardi F, Bella A, Rivera M, et al. 2-week triple therapy for Helicobacter pylori infection is better than 1-week in clinical practice: a large prospective single-center randomized study. Helicobacter. 2006; 11: 562-568.
35. Malfertheiner P, Megraud F, O'Morain C, Bazzoli 47. F, El-Omar E, Graham D, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut. 2007; 56: 772-781.
36. Gisbert JP. The recurrence of Helicobacter pylori 48. infection: incidence and variables inluencing it. A critical review. Am J Gastroenterol. 2005; 100: 2083-2099.
37. Malekzadeh R, Merat S, Derakhshan MH, Siavoshi 49. F, Yazdanbod A, Mikaeli J, et al. Low Helicobacter pylori eradication rates with 4- and 7-day regimens in an Iranian population. J Gastroenterol Hepatol. 2003; 18: 13-17. 50.
38. Malekzadeh R, Mohamadnejad M, Siavoshi F, Mas-sarrat S. Treatment of Helicobacter pylori Iinfection in Iran: low efficacy of recommended western regimens. Arch Iran Med. 2004; 7: 1-8.
39. Malfertheiner P, Bayerdorffer E, Diete U, Gil J, Lind T, Misiuna P, et al. The GU-MACH study: the effect of 1-week omeprazole triple therapy on Helicobacter pylori infection in patients with gastric ulcer. Aliment Pharmacol Ther. 1999; 13: 703-712.
40. Peitz U, Hackelsberger A, Malfertheiner P. A practical approach to patients with refractory Helicobacter pylori infection, or who are re-infected after standard therapy. Drugs. 1999; 57: 905-920.
41. Megraud F. H.pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut. 2004; 53: 1374-1384.
42. Safaralizadeh R, Siavoshi F, Malekzadeh R, Akbari MR, Derakhshan MH, Sohrabi MR, et al. Antimicrobial effectiveness of furazolidone against metroni-dazole-resistant strains of Helicobacter pylori. East Mediterr Health J. 2006; 12: 286-293.
43. Siavoshi F, Safari F, Doratotaj D, Khatami GR, Fal-lahi GH, Mirnaseri MM. Antimicrobial resistance of Helicobacter pylori isolates from Iranian adults and children. Arch Iran Med. 2006; 9: 308-314.
44. Wu H, Shi XD, Wang HT, Liu JX. Resistance of He-licobacter pylori to metronidazole, tetracycline, and amoxycillin. J Antimicrob Chemother. 2000; 46: 121-123.
45. Lang L, Garcia F. Comparison of E-test and disk diffusion assay to evaluate resistance of Helicobacter pylori isolates to amoxicillin, clarithromycin, metro-nidazole and tetracycline in Costa Rica. Int J Antimi-crob Agents. 2004; 24: 572-577.
46. Torres J, Camorlinga-Ponce M, Perez-Perez G, Madrazo-De la Garza A, Dehesa M, Gonzalez-Valencia G, et al. Increasing multidrug resistance in He-licobacter pylori strains isolated from children and adults in Mexico. J Clin Microbiol. 2001; 39: 2677-2680.
47. Mendonca S, Ecclissato C, Sartori MS, Godoy AP, Guerzoni RA, Degger M, et al. Prevalence of Helico-bacter pylori resistance to metronidazole, clarithro-mycin, amoxicillin, tetracycline, and furazolidone in Brazil. Helicobacter. 2000; 5: 79-83.
48. Al-Qurashi AR, El-Morsy F, Al-Quorain AA. Evolution of metronidazole and tetracycline susceptibility pattern in Helicobacter pylori at a hospital in Saudi Arabia. Int J Antimicrob Agents. 2001; 17: 233-236.
49. Aboderin OA, Abdu AR, Odetoyin B, Okeke IN, La-wal OO, Ndububa DA, et al. Antibiotic resistance of Helicobacter pylori from patients in Ile-Ife, Southwest, Nigeria. Afr Health Sci. 2007; 7: 143-147.
50. Wang WH, Wong BC, Mukhopadhyay AK, Berg DE, Cho CH, Lai KC, et al. High prevalence of Helico-bacter pylori infection with dual resistance to metronidazole and clarithromycin in Hong Kong. Aliment Pharmacol Ther. 2000; 14: 901-910.
51. Zullo A, Perna F, Hassan C, Ricci C, Saracino I, Morini S, et al. Primary antibiotic resistance in He-licobacter pylori strains isolated in northern and central Italy. Aliment Pharmacol Ther. 2007; 25: 1429-1434.
52. Boyanova L, Gergova G, Nikolov R, Davidkov L, Kamburov V, Jelev C, et al. Prevalence and evolution of Helicobacter pylori resistance to 6 antibacterial agents over 12 years and correlation between susceptibility testing methods. Diagn Microbiol Infect Dis. 2008; 60: 409-415.
53. Koletzko S, Richy F, Bontems P, Crone J, Kalach N, Monteiro ML, et al. Prospective ulticentre study on antibiotic resistance ofHelicobacter pylori strains obtained from children living in Europe. Gut. 2006; 55: 1711-1716.
54. Glenwright HD, Sidaway DA. The use of metronida-zole in the treatment of acute ulcerative gingivitis. Br Dent J. 1966; 121: 174-177.
55. Roghani HS, Massarrat S, Pahlewanzadeh MR, Dashti M. Effect of two different doses of metroni-dazole and tetracycline in bismuth triple therapy on eradication of Helicobacter pylori and its resistant strains. Eur J Gastroenterol Hepatol. 1999; 11: 709-712.
56. Kaviani MJ, Malekzadeh R, Vahedi H, Sotoudeh M, Kamalian N, Amini M, et al. Various durations of a standard regimen (amoxycillin, metronidazole, colloidal bismuth sub-citrate for 2 weeks or with additional ranitidine for 1 or 2 weeks) on eradication of Helicobacter pylori in Iranian peptic ulcer patients. A randomized controlled trial. Eur J Gastroenterol Hepatol. 2001; 13: 915-919.
57. Osato MS, Reddy R, Graham DY. Metronidazole and clarithromycin resistance amongst Helicobacter pylori isolates from a large metropolitan hospital in the United States. Int J Antimicrob Agents. 1999; 12: 341-347.
58. Wreiber K, Olsson-Liljequist B, Engstrand L. Development of resistant Helicobacter pylori in Sweden. Tendency toward increasing resistance to clarithro-mycin. Lakartidningen. 1999; 96: 582-584.
59. Wolle K, Nilius M, Leodolter A, Muller WA, Malfert-heiner P, Konig W. Prevalence of Helicobacter pylori resistance to several antimicrobial agents in a region of Germany. Eur J Clin Microbiol Infect Dis. 1998; 17: 519-521.
60. Sharara AI, Chedid M, Araj GF, Barada KA, Mourad FH. Prevalence of Helicobacter pylori resistance to metronidazole, clarithromycin, amoxycillin, and tet-racycline in Lebanon. Int J Antimicrob Agents. 2002; 19: 155-158.
61. Bennett PM. Plasmid encoded antibiotic resistance: acquisition and transfer of antibiotic resistance genes in bacteria. Br J Pharmacol. 2008; 153 (suppl 1): S347-S357.
62. Piddock LJ. Clinically relevant chromosomally encoded multidrug resistance eflux pumps in bacteria. Clin Microbiol Rev. 2006; 19: 382-402.
63. Poole K. Eflux-mediated multiresistance in Gram-negative bacteria. Clin Microbiol Infect. 2004; 10: 12-26.
64. Kwon DH, Kim JJ, Lee M, Yamaoka Y, Kato M, Osato MS, et al. Isolation and characterization of tetracycline-resistant clinical isolates of Helicobacter pylori. Antimicrob Agents Chemother. 2000; 44: 3203-3205.
65. Cabrita J, Oleastro M, Matos R, Manhente A, Cabral J, Barros R, et al. Features and trends in Helicobacter pylori antibiotic resistance in Lisbon area, Portugal (1990-1999). J Antimicrob Chemother. 2000; 46: 1029-1031.
66. Megraud F, Marshall BJ. How to treat Helicobacter pylori. First-line, second-line, and future therapies. Gastroenterol Clin North Am. 2000; 29: 759-773, vii.
67. Goodwin CS. Antimicrobial treatment of Helico-bacter pylori infection. Clin Infect Dis. 1997; 25: 1023-1026.
68. Ribeiro ML, Gerrits MM, Benvengo YH, Berning M, Godoy AP, Kuipers EJ, et al. Detection of high-level tetracycline resistance in clinical isolates of Helico-bacter pylori using PCR-RFLP. FEMS Immunol Med Microbiol. 2004; 40: 57-61.
69. Smith JL, Drum DJ, Dai Y, Kim JM, Sanchez S, Maurer JJ, et al. Impact of antimicrobial usage on antimicrobial resistance in commensal Escherichia coli strains colonizing broiler chickens. Appl Environ Microbiol. 2007; 73: 1404-1414.
70. Dechet AM, Scallan E, Gensheimer K, Hoekstra R, Gunderman-King J, Lockett J, et al. Outbreak of multidrug-resistant Salmonella enterica serotype Typhimurium definitive Type 104 infection linked to commercial ground beef, northeastern United States, 2003 - 2004. Clin Infect Dis. 2006; 42: 747-752.
71. Jacobs L, Chenia HY. Characterization of integrons and tetracycline resistance determinants in Aeromo-nas spp. isolated from South African aquaculture systems. Int J Food Microbiol. 2007; 114: 295-306.
72. Kruse H, Sorum H. Transfer of multiple drug resistance plasmids between bacteria of diverse origins in natural microenvironments. Appl Environ Microbiol. 1994; 60: 4015-4021.
73. Wegener HC. Antibiotics in animal feed and their role in resistance development. Curr Opin Microbiol. 2003; 6: 439-445.
74. Butaye P, Devriese LA, Haesebrouck F. Antimicrobial growth promoters used in animal feed: effects of less well known antibiotics on gram-positive bacteria. Clin Microbiol Rev. 2003; 16: 175-188.
75. Lopez-Brea M, Domingo D, Sanchez I, Alarcon T. Evolution of resistance to metronidazole and clar-ithromycin in Helicobacter pylori clinical isolates from Spain. J Antimicrob Chemother. 1997; 40: 279-281.
76. Murray BE. The life and times of the Enterococcus. Clin Microbiol Rev. 1990; 3: 46-65.
77. Godoy AP, Ribeiro ML, Benvengo YH, Vitiello L, Miranda Mde C, Mendonca S, et al. Analysis of antimicrobial susceptibility and virulence factors in Heli-cobacter pylori clinical isolates. BMC Gastroenterol. 2003; 3: 20.
78. Wang G, Wilson TJ, Jiang Q, Taylor DE. Spontaneous mutations that confer antibiotic resistance in Helicobacter pylori. Antimicrob Agents Chemother. 2001; 45: 727-733.
79. van Zwet AA, Vandenbroucke-Grauls CM, Thijs JC, van der Wouden EJ, Gerrits MM, Kusters JG. Stable amoxicillin resistance in Helicobacter pylori. Lancet. 1998; 352: 1595.
80. Khatibian M, Ajvadi Y, Nasseri-Moghaddam S, Ebrahimi-Dariani N, Vahedi H, Zendehdel N, et al. Furazolidone-based, metronidazole-based, or a combination regimen for eradication of Helicobacter pylori in peptic ulcer disease. Arch Iran Med. 2007; 10: 161-167.
81. Malekzadeh R, Ansari R, Vahedi H, Siavoshi F, Alizadeh BZ, Eshraghian MR, et al. Furazolidone versus metronidazole in quadruple therapy for eradication of Helicobacter pylori in duodenal ulcer disease. Aliment Pharmacol Ther. 2000; 14: 299-303.
82. Coelho LG, Leon-Barua R, Quigley EM. Latin-American Consensus Conference on Helicobacter pylori infection. Latin-American National Gastroen-terological Societies affiliated with the Inter-American Association of Gastroenterology (AIGE). Am J Gastroenterol. 2000; 95: 2688-2691.